Valid Ghana · FDA Ghana

GLEMONT 10MG TABLETS (EACH CONTAINS MONTELUKAST 10MG

MONTELUK

FDA/SD.623-030267 MONTELUK 10MG

What it does

Monteluk is a medication used to help manage breathing problems.

Commonly used for: asthma, allergic rhinitis (hay fever)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.623-030267
Registration date
2026-11-03
Expiry date
2029-04-01
Status
Valid
Active ingredient
MONTELUK
Dosage form
MONTELUK
Strength
10MG
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Glenmark Pharmaceuticals
Applicant / LTR
SUPRA PHARM LIMITED
Country of origin
INDIA
Manufacturer location
4V64+XGF Glenmark House, BD Sawant Marg, Parshiwada, Sai Wadi, Andheri East, Mumbai, Maharashtra 400099, India

Source: Food and Drugs Authority · fetched 2026-05-22 02:34:54 · updated 2026-10-20 04:00:11

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Monteluk is a medication used to help manage breathing problems.

What it treats

  • asthma
  • allergic rhinitis (hay fever)

How it works

Monteluk works by blocking substances in the body that cause inflammation and constriction of the airways, making it easier to breathe.

Who it's for

Monteluk is for people with asthma and those who suffer from allergies affecting their breathing.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: monteluk

Montelukast is a leukotriene receptor antagonist that is primarily used to manage asthma and alleviate symptoms of seasonal allergic rhinitis. It works by inhibiting the action of leukotrienes, which are inflammatory mediators that contribute to bronchoconstriction and inflammation in the airways. Montelukast is taken orally and is available in various formulations, including chewable tablets and granules, making it suitable for both adults and children.

Indications

  • Asthma
  • Seasonal allergic rhinitis
  • Chronic rhinosinusitis with asthma

Dosage

Children: For children aged 6 to 14 years, the recommended dose is 5 mg once daily in the

Adults: The usual dose for adults is 10 mg once daily, taken in the evening. In patients with asthma who require additional control, it may be used in conjunction with inhaled corticosteroids.

Mechanism of action

Montelukast selectively binds to cysteinyl leukotriene receptors (CysLT1) on target cells, blocking the action of leukotrienes such as LTC4, LTD4, and LTE4. This inhibition leads to reduced bronchoconstriction, decreased mucus production, and diminished inflammatory responses in the airways, ultimately improving respiratory function and reducing asthma symptoms.

Pharmacodynamics

Montelukast exerts its therapeutic effects through the inhibition of leukotriene-induced bronchoconstriction and inflammation. By blocking the CysLT1 receptors, montelukast reduces airway hyperresponsiveness and improves lung function. The onset of action typically occurs within a few hours of administration, with effects lasting for at least 24 hours, allowing for once-daily dosing.

Pharmacokinetics

Montelukast is well absorbed after oral administration, with peak plasma concentrations occurring approximately 3 to 4 hours post-dose. It has a bioavailability of about 64%, and its absorption is not significantly affected by food. Montelukast is extensively metabolized by the liver, primarily via the cytochrome P450 enzyme CYP2C8, and has a half-life of approximately 2.7 to 5.5 hours. The drug is excreted mainly in the feces and urine, with less than 0.2% of the dose excreted unchanged in urine.

Interactions

  • opicapone+montelukast: Severe (increases exposure)
  • selpercatinib+montelukast: Severe (increases exposure)
  • deferasirox+montelukast: Unknown (increases exposure)
  • leflunomide+montelukast: Unknown (increases exposure)
  • mifepristone+montelukast: Unknown (increases exposure)
  • mitotane+montelukast: Unknown (decreases exposure)
  • teriflunomide+montelukast: Unknown (increases exposure)
  • rifampicin+montelukast: Unknown (decreases exposure)

Pregnancy

Montelukast should only be used in pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Montelukast can be used during breastfeeding, as it is excreted in breast milk in small amounts.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.